Technology

Innoviva

$12.00
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.30 (-2.40%) Today
-$0.21 (-1.72%) As of 1:00 AM UTC after-hours

Why Robinhood?

You can buy or sell Innoviva and other stocks, options, and ETFs commission-free!

About INVA

Innoviva, Inc. Common Stock, also called Innoviva, is engaged in the development, commercialization, and financial management of bio-pharmaceuticals. Its portfolio includes Relvar Breo Ellipta, which is a once-daily combination medicine consisting of a long-acting beta2 agonist, vilanterol, and an inhaled corticosteroid, fluticasone furoate; and Anoro Ellipta, a once-daily medicine combining a long-acting muscarinic antagonist, umeclidinium bromide, LABA, VI. The company was founded by P. Roy Vagelos, Mathai Mammen, and George M. Whitesides in November 1996 and is headquartered in Burlingame, CA. The listed name for INVA is Innoviva, Inc. Common Stock.

CEO
Pavel Raifeld
Employees
6
Headquarters
Burlingame, California
Founded
1996
Market Cap
1.24B
Price-Earnings Ratio
6.31
Dividend Yield
—
Average Volume
517.49K
High Today
$12.62
Low Today
$12.12
Open Price
$12.36
Volume
553.97K
52 Week High
$15.62
52 Week Low
$7.58

Collections

INVA Earnings

$0.00
$0.23
$0.46
$0.69
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
— per share
Actual
Expected Feb 3, After Hours

You May Also Like

UI
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure